Respiratory
| AM103 | ||
Asthma is a chronic inflammatory disorder of the respiratory system, in which inflammation in the airways is due to an immune-mediated process. |
Potential therapeutic targets for asthma medications. |
Leukotrienes are important constituents of the eicosanoid family of inflammatory mediators that have been implicated in asthma. |
AM103 is a novel inhibitor of 5-lipoxygenase activating protein (FLAP) under development as a potential treatment for asthma. |
||
| Ariflo (Cilomilast) - Oral PDE-IV Inhibitor for | ||
COPD is a progressive disorder of the lungs characterised by airflow obstruction. |
Drugs which address the underlying tissue damage in COPD and prevent the progressive decline in lung function which is a hallmark of this disease are urgently needed. |
Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV inhibitor. |
| Xolair - Biological Therapy | ||
The efficacy of Xolair has been investigated in a series of clinical trials which included two pivotal phase III placebo-controlled trials in over 1,000 allergic asthma patients. |
Xolair works by binding to free immunoglobulin E (IgE) in the blood to prevent mast cell degranulation and the release of pharmacologically active substances that are the hallmark of the early allergic inflammatory process. (Source: ABPI) |
It is believed that Xolair will be first marketed as maintenance therapy for the prophylaxis of asthma exacerbations and control of asthma symptoms. |
